NCT03891472View on ClinicalTrials.gov

Clinical Phase II Clinical Study Evaluating the Toxicity and Efficacy of mFOLFIRINOX Associated With SBRT (Stereotactic Radiotherapy) in Patients With Unresectable Locally Advanced Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 1, 2017

Primary Completion Date

July 31, 2019

Study Completion Date

July 31, 2019

Conditions
Cancer of PancreasUnresectable Pancreatic CancerChemotherapy EffectSBRT
Interventions
DRUG

Patients will receive initial chemotherapy, followed by evaluation of the response to the treatment, followed by SBRT, followed by chemotherapy.

mFOLFIRINOX \> SBRT \> mFOLFIRINOX \> Surgical Intervention

Trial Locations (1)

40-514

UCK Katowice, Katowice

All Listed Sponsors
lead

Medical University of Silesia

OTHER

NCT03891472 - Clinical Phase II Clinical Study Evaluating the Toxicity and Efficacy of mFOLFIRINOX Associated With SBRT (Stereotactic Radiotherapy) in Patients With Unresectable Locally Advanced Pancreatic Cancer | Biotech Hunter | Biotech Hunter